Annoucements - Business
We are pleased to announce the appointment of Ms. Kanchan Agarwal as Manager, Finance.
Effective from 3rd May 2021

We are pleased to announce the appointment of Ms. Kanchan Agarwal as Manager, Finance with effect from 3rd May, 2021.

She has completed her CA from Institute of Chartered Accountants of India.

Kanchan brings about 10+ years of experience and has worked in Budgeting, Mis, Finance, Accounting, Audit, SAP Implementation, Compliance, Policies & Process Improvements. She earlier worked with Piramal Foundation, Voltas Ltd. (A Tata Enterprise), Tata Institute of Social Sciences and Pravin Navandar & Co.

She will be responsible for the entire finance function for India entity. She will give 75% of her time to India Business, for which she will report to Mr. Ravinder Kumar Sagar-CEO & Country Head.

She will also be supporting our HQ for 25% of time, for which she will be reporting to Mr. Milan Paleja-Chairman & Managing Director. She will be based at Mumbai Head Office.

Please join us in welcoming Kanchan to the Wellesta family. Wishing her the very best for a long and successful career with Wellesta.
We are pleased to announce the appointment of Ms. Prinka Mittal as Business Development & Marketing Manager for Wellesta Holdings Singapore & her appointment is w.e.f. 16th August 2022.
Effective from 16th Aug 2022

Prior to joining Wellesta, Ms. Prinka worked with Naari Pharma (a Tenshi Group of Lifesciences’ company) as Senior Manager, Business Development for other regulated markets, emerging markets and global strategic accounts. Her career spans over 10 years of comprehensive experience in International Business Development for regulated markets like Europe, Australia & NZ, Canada and emerging markets. Ms. Prinka has handled multiple roles in her previous assignments including project management, portfolio designing and leading key launches in various markets under the larger role of business development.

She started her career from Strides Pharma as an executive in business development for domestic division and moved on to international business development in subsequent roles. She has also worked for a brief period at Biocon Ltd. as an International Marketing Executive for API Division - APAC and South Africa markets.

Ms. Prinka Mittal pursued her B.Pharm and MBA from Narsee Monjee Institute of Management Studies (NMIMS) Mumbai.

We are sure that Ms Mittal's rich experience and leadership will support us achieve our vision and mission. She will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Prinka Mittal to the Wellesta family and wish her great success.
We are pleased to announce the appointment of Mr. Vishwajit Kamat as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies.
Effective from 20th June 2022

Mr. Vishwajit Kamat has been appointed as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies with effect from June 20th 2022.Mr. Kamat is a seasoned Business leader with over 39 years of experience in the pharmaceutical industry in different responsibilities across the sales, marketing & operational value chain. In his last role , he was SVP & Cluster Head with Zydus Cadila, India.

His journey started with Cipla and he was associated with other firms like Mylan, UCB, Johnson & Johnson, Bayer Zydus Pharma, and German Remedies (Zydus Group). These assignments have enabled distinguished perspective and exposure to varied business models and a plethora of therapeutic segments. In his previous assignments, he has successfully launched business units with Aristo (Otsira Genetica), German Remedies, Zydus (Evona), and Mylan.

He has built & nurtured values while creating cohesive winning teams for driving business and ensuring their career growth. He has built businesses adhering to global compliance standards, thereby bringing sustainability and adaptability to enduring profitability.

Mr. Kamat holds a graduate degree in science from Dharwad University, Karnataka and he has pursued studies in management with two degrees from reputed institutes - Masters in Marketing Management from NMIMS, Mumbai University and Executive MBA - General management from IIM Ahmedabad. He is actively engaged as visiting faculty, keynote speaker and guest lecturer with management institutions of repute like the NMIMS University, Welingkar School of Management Studies, Xavier’s Institute of Management & Research in Mumbai. It remains a key aspect in his learning curve to share his thoughts and learn from the newness and disruption created by younger minds.

He will be responsible to lead Commercial Organisation for Wellesta India organisation and will report to Wellesta India CEO, Ravi Sagar. He shall also lead Gynaec franchise across Wellesta Group companies for which he will report to Mr. Milan Paleja, Chairman & MD of Wellesta Group. We are sure that Mr. Kamat’s experience and leadership will help and support our India business plan to achieve our Vision and Mission. We welcome Mr. Vishwajit Kamat to Wellesta family and wish him great success in this new position.

We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as CEO and Country Head for India with effect from Feb 1st 2021.
Effective from 1st Feb 2021

Mr. Ravinder Kumar Sagar has been appointed as CEO and Country Head of India with effect from Feb 1st 2021. Mr. Sagar is a seasoned business leader with 39 years of experience, and an ambitious visionary who believes in looking at problems as opportunities. He was previously associated with Novartis for over three decades.

His experience spans over the entire country and has led businesses in specialties like Transplant & Immunology, Oncology, Established brands business, Respiratory and most recently with Key Accounts Management, which cuts across all the businesses of the organization.

He started his career as a Medical Representative and rose to rank as Area Manager, Regional Manager, Business Head, and also a member of the Pharma Executive Committee in his journey with Novartis. He managed Sales, Marketing, Sales-Force Effectiveness, FF deployment project post-merger in Novartis, Third-party FF, and Key Accounts Management. KAM became the benchmark for not only Indian Pharma but also in the AMEA (Asia, Middle East, Africa) region. He was the first-time recipient of the "Manager of the Year" award in 2018, which was awarded by the regional head. Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters in Marketing Management from NMIMS Mumbai.

We at Wellesta see good opportunities in Indian Healthcare Market, as well as ventures for Wellesta to grow and make strong progress. We are sure that Mr. Sagar's experience and leadership will help guide our India business plan to achieve our vision and missions in India. Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India, and also the Chairman and MD of the Wellesta Group.

We wish Mr. Ravinder Kumar Sagar great success in this new position.
We are pleased to announce our Strategic Business Alliance in India with Parazelsus through its subsidiary company Wellesta Healthcare Pvt. Ltd, India.
Effective from July, 2020

Wellesta Holdings Pte.Ltd is pleased to announce strategic alliance in India with Parazelsus through its subsidiary company in India, Wellesta Healthcare Pvt. Ltd.

Parazelsus is an MNC company founded by Peter Zuellig in 2007 and operates in multiple countries including India, specializing in Distribution & Logistics. The Company is led by Markus Haefeli as Managing Director. Parazelsus India with its focus on Distribution and Logistics in the Healthcare sector, decided to partner with Wellesta in India for its CSO & Sales and Marketing business.

Wellesta’s core strength is Marketing, Brand Management, Sales & Operations with world class standards in its business approach and compliance. We foresee this partnership will make a Perfect Fit by offering an end-to-end business solution to business partners. With this decision 120 employees have moved from Parazelsus to Wellesta in India.

This will help us achieve our goal to provide high quality end to end professional services and support while providing high quality healthcare products at optimum prices, to support improving health for patients. Our focus would be driven through our dedicated efforts, strong in-market experience, determination and commitment.
We are pleased to announce the appointment of Mr. Prameet Shah as Manager, Technical Operations.
Effective from 1st Jul 2020

We are pleased to announce that . Prameet K Shah has joined us as Manager- Technical Operations. He will be reporting to Mr. Dinesh Nair - Director- Supply Chain and will be based at Head Office.

He has completed his M.Pharm from Poona College of Pharmacy – Pune and Executive MBA from ITM Mumbai.

He brings about 30+ years of experience in Planning, cross-functional coordination, production and product supply management, New Products sourcing, Pricing, costing and negotiations ,procurement management, Business development for contract manufacturing and earlier worked for Neon laboratories Ltd, Themis Medicare Ltd, Arvind Remedies Ltd, Unimark Remedies Ltd, Mission Vivacare Ltd, JB Chemicals, VHB Life science and Novartis India Ltd.

Please join us in welcoming Prameet to the Wellesta family. Wishing him the very best for a long and fruitful career with Wellesta.
We are pleased to announce the appointment of Ms. Kiran Alva as Manager, HR.
Effective from 03rd Feb 2020

We are pleased to announce the appointment of Ms. Kiran Alva as Manager, HR.

She has completed her MBA from H.K Institute of Management Studies & Research through Mumbai University and Master in labour Management from Annamalai University.

She brings about 8.5 years of experience in pharmaceuticals industries and Handled role ranging from Talent acquisition, Employee Engagement, Formulating Job Description & Recruitment Rules, KPI setting, and Performance Management Process.

She has earlier worked for Elder Health Care Ltd. (Elder Pharmaceutical Division). Fullife Health Care Pvt. Ltd, Regaliz Medicare Ltd and Eurolife Health Care Pvt.Ltd.

We welcome Ms. Kiran Alva to our Wellesta family and wish her great success in this role.
We are pleased to announce the appointment of Mr. Sharad Lad as Manager, Finance.
Effective from 1st Feb 2020

We are pleased to announce the appointment of Mr. Sharad Lad as Manager, Finance.

He has completed his Chartered Accountancy from ICAI.

He brings about 4 years of experience and Handled Overall Accounting & Financial activities , Global consolidated Financial Reporting to Management, Financial Budgets & forecasting Analysis for a division.

He has earlier worked for Parazelsus India Pvt Ltd.

We welcome Mr.Sharad Lad to our Wellesta family and wish him great success in this role.
We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as Senior Advisor to India Leadership Team for India Business.
Effective from 15th Jul 2020

We are pleased to announce that Mr. Ravinder Kumar Sagar has been appointed as Senior Advisor to India Leadership Team with effect from 15th July, 2020. Mr Sagar is a seasoned business leader with 39 years of experience and a visionary who believes in looking at problems as opportunities and always aiming for slightly impossible objectives. He was previously associated with Novartis for over 3 decades.

His experience spans over entire country and has lead businesses like Transplant & Immunology, Oncology, Established brands business, Respiratory and more recently with Key Accounts Management which cuts across all the businesses of the organization

His career started as Medical Rep, rose in to rank as Area Manager, Regional Manager, Business Head and member of Pharma Executive Committee in his 3 decades journey with Novartis. He managed Sales, Marketing, SFE (Sales Force Effectiveness), FF deployment project post- merger in Novartis, Third party FF and Key accounts management. KAM became the benchmark for not only Indian Pharma but also in the AMEA region. He was awarded “Manager of the year in 2018” by the regional head which was awarded for the first time to any individual in the past.

Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters in Marketing Management from NMIMS Mumbai.

We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Sagar's experience & leadership will help our India Business plan to achieve our Vision & Mission in India.

Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman &MD of the Wellesta Group.

We welcome Mr. Ravi Kumar Sagar to our Wellesta family and wish him great success in this role.
We are pleased to announce the appointment of Mr. Kamal Anand as Director, Sales for Wellesta Healthcare Pvt. Ltd, India.
Effective from 1st Dec 2019

Mr. Kamal Anand has been appointed Director, Sales for India business with effect from 1st December, 2019. Mr. Anand is a competent professional with over 35 years of experience in Strategic Planning, Sales & Marketing and Business Development. In his last role, he was BU Head, Consumer Products Divison at Plethico Pharmaceuticals Ltd.

He possesses a strong leadership record and has a deep understanding of the consumer and business landscape across geographies having worked in the FMCG and Healthcare sector both in India and abroad. He started his career after his MBA as a Management Trainee in Ranbaxy, and later worked in DFM Foods, Dabur, Novartis and Plethico.

Mr. Anand holds an undergraduate and post graduate degree in Life Sciences as well as LLB degree from Delhi University and an MBA from Jodhpur University.

We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Anand's rich experience & leadership will help us to achieve our Vision & Mission in India.

Mr. Anand will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Kamal Anand, who is originally from Delhi and is now based in Mumbai, to our Wellesta family. He will lead Sales Organisation & be a part of India Leadership team.
We are pleased to announce the appointment of Mr. Sharad Virmani as Director, Partner Business for Wellesta Healthcare Pvt. Ltd.
Effective from 1st Feb 2020

Mr. Sharad Virmani has been appointed as Director, Partner Business for Wellesta Healthcare Pvt. Ltd with effect from 1st February, 2020. Mr. Virmani is a very well-rounded professional with over 35 years of experience in Pharma, Capital Equipment, Medical Devices, Diagnostics, Surgical & Healthcare in MNC & Indian Companies. In his last role, he was Country Head and Business Director - South Asia for Sales, Marketing & Contract Sales Operations at Parazelsus Pte Ltd.

His experience in business spans over Pan-India, Bangladesh and Nepal for both MNC’s and Indian Companies. It encompasses of setting up and managing Contract Sales Operations & New Business Divisions with exposure to handling multiple therapeutic segments.

His career started as a Medical Representative at Serdia and Hoechst (Sanofi) and later worked with Torrent, AstraZeneca, Nicholas Piramal, Micro – BAL, Pharmalink (Invida), Comed and Parazelsus.

Mr. Virmani is a Science Graduate from Kanpur University and has a Diploma in Export Management from Indian Institute of Export Management.

We at Wellesta are very optimistic about opportunities in the Indian Healthcare Market & opportunities for Wellesta to grow and make strong progress. We are sure that Mr. Virmani's rounded experience & leadership will help to achieve our Vision & Mission in India.

Mr. Virmani will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Sharad Virmani, originally from Delhi who is now based in Mumbai, to our Wellesta family and we look forward for him to make our company reach greater heights with his contribution.
We are pleased to announce the appointment of Mr. Dinesh Nair as Director, Supply Chain for India Business.
Effective from 1st Dec 2019

Mr. Dinesh Nair has been appointed as Director, Supply Chain for Wellesta Healthcare Pvt. Ltd with effect from 1st December, 2019. Mr. Nair is a seasoned business leader with over 35 years of experience in Pharmaceutical, OTC, Medical Nutrition & Food Industry locally & internationally. He was previously Managing Partner at Integratos India LLP, India.

His experience in business spans over Asia Pacific and Africa for both MNC’s and Indian Companies. It encompasses the setting-up of new businesses, opening-up new Emerging markets, turning around under-performing businesses, establishing sales & distribution networks, managing P & L and leading cross-cultural & cross- functional teams across geographies.

His career started as Distribution Manger at Themis Pharmaceuticals and Medley Pharma later worked at First Arabian department stores, Novartis, Nestle, Equant Consultants Pvt. Ltd and Integratos India LLP.

Mr. Nair completed his post graduate diploma in Marketing & Sales Management and Computer Applications. He has obtained a Bachelor degree in Science from Mumbai University, India.

We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Nair's experience & leadership will help to achieve our Vision & Mission in India.

Mr. Nair will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Dinesh Nair, a Keralite who is now based in Mumbai, to our Wellesta family and wish him great success in his future endeavours.
We are pleased to announce the appointment of Mr. Partha Dutt as Director, Marketing & New Product Strategy for India business.
Effective from 1st Mar 2020

Mr. Partha Dutt has been appointed as Director, Marketing & New Product Strategy for Wellesta Healthcare Pvt. Ltd with effect from March, 2020. Mr. Dutt is a competent professional with over 22 years of experience in Consumer Healthcare, OTC and FMCG (Health & Wellness). In his previous role as CEO of Nutrite Healthcare, he was responsible for setting up the nutraceutical business from scratch.

He comes with extensive knowledge in various categories and experience in strategic and operational front. His strength lies in his ability of working collaboratively with cross-functional teams, taking high levels of ownership and adding value to their decision-making.

Mr. Dutt has been in various leadership roles across leading companies like 3M, VLCC, GSK and Novartis. His experience spans across various categories like VMS, cough/cold/fever, pain and inflammation, nutritional supplements, wound care etc. Mr. Dutt holds a MMS (Marketing)- Business Management and B.Pharm degree from Mumbai University.

We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that the addition of Mr Partha Dutt to team will help us to achieve our Vision & Mission in India.

Mr. Dutt will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Partha Dutt, who is originally from Kolkata and now based in Mumbai to lead Wellesta India's Marketing & New Product Strategy with his expertise and strategic prowess.
We are pleased to announce the appointment of Mr. Paul Lim as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.
Effective from 1st Mar 2020

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020.

Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced commercial leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.

With his expertise and robust experience, he has held various key commercial roles in multinational companies such as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the pharmaceutical franchise of ophthalmology as Business Unit Head.

He holds Bachelor of Business degree from the University of Central Queensland and has completed his coursework for Global MBA from University of London.

We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets. With addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our company.

Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman & MD of Wellesta Group.

We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his dedicated contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead for the OTC Businesses in Malaysia and Indonesia.
We are pleased to announce the appointment of Mr. Yohannes Sinaga as Country Manager, PT Wellesta CPI Indonesia.
Effective from 1st May 2020

Mr. Yohannes Sinaga has been appointed as the Country Manager for PT Wellesta CPI Indonesia, effective from 1st May 2020.

His last position was Chief Marketing Officer for AstraZeneca Indonesia. He has extensive experience with 15 years in pharmaceutical industry.

Mr. Sinaga has experience in various positions including sales and marketing, as well as various experiences in varied therapeutic areas. He has extensive engagement with Medical Association Groups including the association of Pediatrician, Psychiatry, Internal Medicine, Hematology – Oncology, Surgical Oncology, Pathology, Pulmonology, Hepatology, Nephrology, Virology, Neurology, Rheumatology, Urology, Gynecology, as well as with Government Stakeholders.

Mr. Sinaga’s career started as Product Specialist for Novartis in 2006, then moved to marketing role as a Product Manager, he worked with Novartis for 5 years. In 2011, he decided to move to Roche Indonesia as an Oncology Product Manager, 1 year later was promoted as a Group Product Manager and later was appointed as Business Unit Head. He joined AstraZeneca (AZ) in 2016 as a Business Unit Director for Respiratory Disease as well as to leading Core Products and later to lead the Learning & Development Department. Mr. Sinaga was a member of AstraZeneca International Marketing Excellence Champion with the role to set Respiratory strategy plan to countries in international region.

Mr. Sinaga holds MBA from IPMI International Business School in Jakarta as well as a Certified Pharmacist/Apothecary from University of Padjadjaran Bandung – Indonesia.

We at Wellesta are very optimistic about Indonesian Healthcare Market & opportunities for Wellesta to progress. We are sure that with Mr. Sinaga’s leadership the Indonesia team will help achieve our Vision & Mission. Mr. Sinaga will report to Milan Paleja, Director of PT Wellesta CPI Healthcare & also Chairman & MD of Wellesta Group.

We welcome Mr. Yohannes Sinaga to Wellesta family and wish him great success in his new position.
We are pleased to announce partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia.
Acquired from 1st Dec 2019

We are very pleased to announce our partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia from current shareholders. It will now operate under the new name PT Wellesta CPI Healthcare and will be based from Jakarta. PT Citra Pharma Indonesia is in successful operations for last 12-years and have been partner with MNC players in Pharma and Healthcare sector in the Indonesian market. PT Citra Pharma provides medical sales & marketing services to MNC in Indonesia with successful and compliant track record.

This company was founded by Pak Budi, Pak Chan, Pak Freddy & Pak Agus. At present PT Wellesta CPI is led by Pak Freddy Hidajat as President Director. Indonesia is one of the fastest growing pharmaceutical markets in Asia and offers us good opportunity to partner with present MNCs in the country & companies who want to enter Indonesian market.

Our goal is to provide high quality professional services and support provide high quality healthcare products at optimum price to improve health to masses. We foresee this partnership will help accomplish our Vision and Mission through PT Wellesta CPI Healthcare in Indonesia. Our focus would be driven through our dedicated efforts, strong in-market experience, determination and veracity.
Abdul Latif Jameel Health and Wellesta announce collaboration to bring the innovative Butterfly iQ+TM Point-Of-Care Ultrasound (POCUS) solution to serve the medical imaging needs of over 1.3 billion people across India
Effective from 1st October 2022.


  • The Butterfly iQ+ is the only ultrasound transducer that can perform whole-body imaging in a single handheld probe using semiconductor technology to provide point-of-care ultrasound-driven insights.
  • Founded in 2020, Abdul Latif Jameel Health was created as a response to the ongoing global disparity in access to modern medical care, focusing on accelerating healthcare inclusion across the Global South.
Dubai UAE & Mumbai, India: October 19, 2022:
Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Wellesta Holdings Pte. Ltd., a Singapore headquartered company providing marketing and commercialization support to the healthcare sector in South East Asia, India & partnering in MENA, today announced an important new agreement for the marketing and distribution of the Butterfly iQ+TM point-of-care ultrasound device in The Republic of India.

The innovative Butterfly iQ+TM1 is the world's first single probe, whole-body handheld point-of-care ultrasound solution. As part of its new agreement with Abdul Latif Jameel Health, Wellesta will register Butterfly iQ+TM in India and start promoting and selling the product in the country in the fourth quarter of 2022, bringing this technology to a potential 1.2 million registered physicians in the country2.

Today, more than 4.7 billion around the world lack access to medical imaging3 , from underserved communities in the United States to remote areas of Africa. The Butterfly iQ+TM aims to remedy this situation. Fusing semiconductors, artificial intelligence, and cloud technology, Butterfly has made it possible to usher in a new era of medical imaging and with it, healthcare.

This new collaboration will offer greater distribution of Butterfly iQ+TM to physicians in India thereby expanding the capabilities of the practitioners in making informed decisions thereby accelerating access to modern medical care for those who need it most.

Butterfly iQ+TM, is revolutionizing medical imaging. It is a hand-held 4 in 1 single probe whole-body innovative point-of-care ultrasound device powered by the world’s only Ultrasound–on-Chip™ technology.

This point of care device with over 20 default pre-sets is compatible with both iOS and Android smart devices and comes complete with battery back, wireless charging, cloud storage, customized app., software and AI support.

Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+TM transforms what can sometimes be complex processes, into one connected and integrated point-of-care ultrasound (POCUS) system to help collect advanced imaging, perform rapid assessments, and guide critical procedures. It allows the sharing of results seamlessly with doctors across the globe to help read and interpret scans.

Speaking about this new collaboration, Mr. Milan Paleja, Chairman and Managing Director, Wellesta, said: “I am very excited to partner with Abdul Latif Jameel Health to market Butterfly iQ+TM in India to bring this breakthrough Ultrasound-on-ChipTM technology in the Butterfly probe to this market. Its versatile, innovative ultrasound solution will assist healthcare professionals to obtain point-of-care Ultrasound-driven insights - – across the vast country with a geographically disperse population to improve access to primary healthcare.”

Mr. Paleja added his thanks to deal advisor, Healthark Insights who supported this collaboration with Abdul Latif Jameel Health.

Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health added: “Abdul Latif Jameel is addressing tangible real-world needs today, for a better tomorrow. We are focused on health care inclusion, accelerating access to modern medical care for those who need it most.

“We believe in realizing the true power of deep local knowledge, relationships, and partnerships to get the very best results for the communities we serve. In India, I am proud to collaborate with Wellesta who share our vision of improving live and lives across the Global South.”

[1] Butterfly iQ+TM is a Class IIa / Class B / Class II / Class II / IIa ultrasound system designed for diagnostic imaging by trained healthcare professionals. Carefully read and understand all cautions, warnings and operational instructions prior to use.

[2] In 2020, there were over 1.2 million doctors registered with the Indian Medical Council.

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704652/#R3
Note to Editors:

About Wellesta
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

Wellesta Holdings operate in a spectrum of business verticals under our partner brands and own brands including pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta works as an extended arm for our principals through win-win partnership and provides superior quality products and services at the right price, by working at full compliance and transparency in our business approach. This joint collaboration supports the mission of Wellesta to provide cost-effective and high-quality products and services and help to deliver better patient outcomes in healthcare.

For further information, visit: www.wellesta.com and our LinkedIn page.

About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.

Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.

The Jameel Investment Management Company (JIMCO) the global investment arm of the Jameel Family, actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

For further information, visit: https://aljhealth.com and our brand video here.
Media Contact: Email aljhealth@edelman.com or telephone: +971 54 996 9935 (GMT +4 hours UAE)
For general inquiries: info@aljhealth.com
For adverse event reporting or medical enquiries: safety@aljhealth.com / T:+971 4 448 0905

Copyright Notice and Disclaimer
© Meddist Company Ltd. (Abdul Latif Jameel Health). All rights fully reserved. The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.

The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.

This document may contain forward-looking statements. Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective management.

Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases. However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities. Should any of such expectations or Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.

No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

Important Note:
The Butterfly iQ+ product is not yet registered/marketed in all markets.
No News Found